Search

Your search keyword '"H M, Kantarjian"' showing total 116 results

Search Constraints

Start Over You searched for: Author "H M, Kantarjian" Remove constraint Author: "H M, Kantarjian"
116 results on '"H M, Kantarjian"'

Search Results

1. Moving toward individualized target-based therapies in acute myeloid leukemia

2. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

4. Fludarabine therapy in macroglobulinemic lymphoma

5. General Approach to the Therapy of Adult Acute Lymphoblastic Leukemia

6. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity

7. Homoharringtonine: history, current research, and future direction

8. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase

9. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias

10. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

11. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia

12. Adult acute lymphocytic leukemia. Future research directions

13. Adult acute lymphocytic leukemia. Introduction and questions related to current programs

14. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia

15. Therapeutic choices in younger patients with chronic myelogenous leukemia

16. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha

17. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia

18. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia

19. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

20. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance

21. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells

22. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance

23. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?

24. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

25. Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture

27. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow

28. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia

30. Natural history and staging of chronic myelogenous leukaemia

31. Decitabine studies in chronic and acute myelogenous leukemia

32. Pneumonia during remission induction chemotherapy in patients with AML or MDS

33. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults

34. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first

35. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience

36. Treatment of myelogenous leukemia: current status and investigational options

37. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes

38. Acute lymphoblastic leukemia following preleukemic syndromes in adults

39. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181)

40. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution

41. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy

42. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis

43. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment

44. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes

45. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia

46. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations

47. p16INK4A and p15INK4B gene deletions in primary leukemias

48. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia

49. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF)

50. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

Catalog

Books, media, physical & digital resources